TARA

Protara TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$9.00

+107.4% vs current

Most likely

Base case

45%

Probability

Target price

$5.00

+15.2% vs current

B-

Bear case

30%

Probability

Target price

$2.75

-36.6% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Primary-source evidence supports only a cautious monitoring view rather than a strong directional call. March 2026 disclosures confirmed meaningful NMIBC efficacy and preserved 2026 milestone timing, while January 2026 releases added regulatory support in lymphatic malformations and a second late-stage program. Even so, deterministic signals remain neutral-to-slightly negative, coverage is limited, and the stock stays exposed to binary readouts, warrant-related supply, and normal small-cap biotech execution volatility.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-06-29catalystWarrant overhang resolves by June 29, 2026High impact

On March 30, 2026, Protara said the average six-month complete response rate for the first 25 BCG-unresponsive ADVANCED-2 patients was 68.0%, which fixed the exercise window for the April 2024 common warrants at $5.25 per share through June 29, 2026. That creates a near-term setup where warrant exercises could improve liquidity but also cap upside if holders sell into strength [#8-K-2026-03-30].

2026-06-30eventLM regulatory-path update in 1H 2026High impact

Management said TARA-002 received Breakthrough Therapy and Fast Track designations in pediatric lymphatic malformations, was selected for FDA's CMC pilot program, and that the company expects to provide a regulatory update on the path to registration in the first half of 2026. A clear FDA path could materially improve confidence in a second registrational route, but timing and scope remain company-guided rather than fixed by the agency [#PR-2026-01-05][#PR-2026-03-10].

2026-10-31catalystADVANCED-2 enrollment completion and ADVANCED-3 start in 2H 2026High impact

In its March 10, 2026 business update, Protara said it expects to complete enrollment of the BCG-unresponsive registrational cohort in ADVANCED-2 and initiate the ADVANCED-3 registrational trial in BCG-naive patients in the second half of 2026. Hitting both milestones would strengthen execution credibility around the lead NMIBC program, but slippage would reinforce the market's wait-and-see stance [#PR-2026-03-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology